Compare Harley-Davidson Inc (HOG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Sana Biotechnology Inc — how do they compare? Harley-Davidson Inc trades at $25.85 (market cap $2.78B), while Sana Biotechnology Inc trades at $3.78 (market cap $1.13B). The key difference: Harley-Davidson Inc is far larger — about 2.5× Sana Biotechnology Inc's market cap, and Harley-Davidson Inc pays a 2.75% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| HOG | SANA | |
|---|---|---|
Market Cap | $2.78B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $5.92 |
52-Week Low | $17.19 | $2.68 |
Enterprise Value | $3.19B | $1.05B |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.10, up 0.35% with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with an EPS beat ($0.75 vs. $0.645 expected) but revenue challenges, while raising full-year guidance. Valuation appears reasonable with P/E of 14.84 and P/S of 0.72, though profitability metrics show pressure with net margin at 4.78%.
The outlook remains cautiously optimistic with analyst consensus at $26.00 target. Key opportunities include North American sales strength and cost-cutting initiatives, while risks involve raw material costs and competitive pressures. Institutional activity shows mixed signals with recent large purchases and sales.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
